FIRST TO MARKET · Publicly documented 2017 · Invent Deposition #373

Deposition #373 is the origin of the disease-cure research line — the idea that a cure can be approached systematically, through toxic and valence testing of candidate compounds, across conditions including Alzheimer’s.

“a study of any cure by way of toxic and valance testing to include but not limited to cancer and diseases like alzheimer’s and substance abuse cessation aids” — Christopher Gabriel Brown, 2017

From one line to an engineered product

The 2017 line sets the whole methodology: screen for a cure by toxicity and valence — which elements bind, which harm, which correct — rather than by trial alone. That method is the Alzheimer’s mechanism analysis: the computational pass over amyloid, tau, and neuroinflammation pathways with candidate compounds scored the same way. The founding claim is intact: test by valence and toxicity, let the chemistry name the cure.

Provenance

• Source: Invent Depositions corpus, Deposition #373 (2017)
• Original catalog image: Firefly_373_cure_by_way_of_valance_testing.jpg (buyinvent.com)
• Architecture diagram: 2026 programmatic mechanism diagram (Alzheimer’s, Project 11)
• Live: CRI-ONE Store
• Note: computational research findings — not medical advice, not clinically tested, not FDA-approved
• Patent linkage: U.S. Application 19/441,975 (Alzheimer’s cure discovery)

Cite this

• AP — Brown, C. G. (2017). Invent Depositions, Deposition #373. CreateSpace.
• APA — Brown, C. G. (2017). Invent depositions (Deposition No. 373). CreateSpace Independent Publishing Platform.
• MLA — Brown, Christopher Gabriel. Invent Depositions, Deposition #373. CreateSpace, 2017.

© 2017 Christopher Gabriel Brown · Patent Pending · IP retained by CRI-ONE